BACE Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S2156	LY2886721	LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.	Acta Neuropathol, 2025, 149(1):10 Foods, 2024, 13(18)2858 Stem Cell Reports, 2023, 18(7):1516-1533
S1528	LY2811376	LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic Proteases including cathepsin D, pepsin, or renin. Phase 1.	Glycobiology, 2023, 33(4):325-341 J Agric Food Chem, 2022, 70(5):1536-1546 Sci Rep, 2022, 12(1):7
S8173	Verubecestat (MK-8931) Trifluoroacetate	Verubecestat (MK-8931) Trifluoroacetate is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.	Analyst, 2022, 10.1039/d2an00031h Nat Cancer, 2021, 2(11):1136-1151 Alzheimers Dement (N Y), 2020, 6(1):e12038
S8564	Verubecestat (MK-8931)	MK-8931 (Verubecestat) is a potent and selective beta-secretase (also known as Beta-site APP-cleaving enzyme 1) inhibitor.	Int J Mol Sci, 2025, 26(8)3756 J Cereb Blood Flow Metab, 2023, 43(2_suppl):66-77 Biol Psychiatry, 2022, 92(2):116-126
S7731	AZD3839	AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.	Elife, 2025, 13RP100968 Analyst, 2022, 10.1039/d2an00031h Genome Med, 2021, 13(1):168
S8193	Lanabecestat (AZD3293)	Lanabecestat (AZD3293, LY3314814) is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor with an inhibitory constant Ki of 0.4 nM.	Analyst, 2022, 10.1039/d2an00031h Alzheimers Res Ther, 2020, 26;12(1):63 Commun Biol, 2020, 3(1):728
S3326	Phytic acid dipotassium salt	Phytic acid dipotassium salt (Phytic acid potassium, IP6 (PS)), an endogenous metabolite in rice grain extract and digest, inhibits β-secretase 1 (BACE1) with IC50 of approximately 0.25 μM.	Analyst, 2022, 10.1039/d2an00031h
S8600	Elenbecestat	Elenbecestat (E2609) is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.	EMBO Rep, 2025, 10.1038/s44319-025-00442-4
S6503	LX2343	LX2343 is a multi-target agent that exhibits a high capability for ameliorating multi-abnormalities of AD pathogenesis. It is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM.
S3835	Loganin	Loganin (Loganoside) is an iridoid glycoside first isolated from the seeds of Strychnos nux-vomica, a member of the Loganiaceae family. This compound is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM and also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively.
S4657	Eslicarbazepine Acetate	Eslicarbazepine Acetate (BIA 2093, Zebinix, Exalief, Stedesa, Aptiom), an antiepileptic drug, is a dual inhibitor of β-Secretase and voltage-gated Sodium Channel.
S3245	Nodakenetin	Nodakenetin (NANI), a plant-derived coumarin isolated from Angelica decursiva, inhibits α-glucosidase, PTP1B, rat lens aldose reductase (RLAR), AChE, BChE, and β-site amyloid precursor protein cleaving enzyme 1 (BACE1). This compound alters the protein expression of Bax and Bcl-2, and prompts mitochondrial apoptosis. It exhibits anti-tumour activity.